Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of MMPs. This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily,...
Date First Received: February 27, 2008
Last Updated: February 27, 2008
Verified by: Kaunas University of Medicine, February 2008
Clinical Trial Phase: N/A | Start Date:
Overall Status: Recruiting
Estimated Enrollment: 34
Brief Summary
Condition Keyword(s):
Intervention(s):
Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of MMPs.
This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily, or placebo. Main outcome variable is pain (VAS) at three weeks.
Serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases are measured.
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Placebo
- Drug: Doxycycline
Arms, Groups and Cohorts in this Clinical Trial
- Placebo Comparator: 2
- Experimental: Doxycycline
- 100 mg twice daily
Outcome Measures for this Clinical Trial
Primary Measures
- Pain (VAS)
- Safety Issue?: No
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age 18-65
- Pain at the lateral side of the elbow ≥8 weeks
- Local tenderness on palpation of the lateral epicondyle
- Pain on resisted extension of the wrist
Exclusion Criteria:
- Rheumatic disorder
- History of fibromyalgia or generalised pain
- Elbow surgery (on the painful side)
- Active infection
- Glucocorticoid treatment during the duration of symtoms of epicondylalgia
- NSAID use within 1 w before presentation and during the study
- Pregnancy
- Taking drug that might interact with doxycycline
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Kaunas University of Medicine
Overall Clinical Trial Officials and Contacts
Overall Contact: Alfredas Smailys, MD, PhD +370 37 327201 smailys@takas.lt
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00631501
Study ID Number: BE-2-47
ClinicalTrials.gov Identifier: NCT00631501
Health Authority: Lithuania: Kaunas University of Medicine
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
